What Analyst Recommend? MiMedx Group, Inc. (MDXG) stock is worth at $ $11.36

Lester Mason
November 18, 2017

As of the end of the quarter Balyasny Asset Management LLC had sold a total of 1,881 shares trimming its holdings by 0.1%. The stock rose 0.06% or $0.05 reaching $88. About 734,006 shares traded. It has underperformed by 11.01% the S&P500.

October 30 investment analysts at Needham & Company LLC held the stock rating at "Buy" targeting a price of $21.00. Therefore 75% are positive. MiMedx Group had 21 analyst reports since July 29, 2015 according to SRatingsIntel. Needham downgraded the stock to "Buy" rating in Wednesday, July 29 report. On August 3 analysts at Needham & Company LLC updated coverage of MDXG with an initial rating of "Buy". Needham has "Buy" rating and $13 target. Wells Fargo initiated Fate Therapeutics Inc (NASDAQ:FATE) on Friday, December 4 with "Outperform" rating.

Analysts await MiMedx Group Inc (NASDAQ:MDXG) to report earnings on February, 22. The rating was maintained by Piper Jaffray with "Buy" on Thursday, September 21. Lake Street Capital lifted their price target on shares of MiMedx Group from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, July 28th. The stock has "Buy" rating by Needham on Monday, June 26. The firm has "Buy" rating by KeyBanc Capital Markets given on Tuesday, September 19. About 19,692 shares traded.

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The firm has a market cap of $1,260.00, a price-to-earnings ratio of 56.24, a price-to-earnings-growth ratio of 2.81 and a beta of 0.91. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Investors sentiment increased to 2.02 in 2017 Q2. Its up 0.59, from 1.43 in 2017Q1.

Investors are feeling more bearish on shares of the company if you watch the change in short interest. Ubs Asset Mgmt Americas invested 0% in MiMedx Group Inc (NASDAQ:MDXG). The stock of MiMedx Group Inc (NASDAQ:MDXG) earned "Overweight" rating by First Analysis on Wednesday, January 20. Lakeview Capital Prns Ltd reported 67,026 shares. Clarivest Asset Mngmt Limited Liability Company accumulated 0% or 7,153 shares. Finally, Northern Trust Corp raised its stake in shares of MiMedx Group by 2.2% in the 2nd quarter.


Returns and Valuations for L Brands, Inc.

Tiedemann Wealth Management, LLC says it decreased its ownership in Mimedx Group Inc by 0.1% in a 13F filing with the SEC. Pinebridge Investments Lp accumulated 13,438 shares or 0.01% of the stock. About shares traded. MiMedx Group Inc (NASDAQ:MDXG) has risen 107.87% since November 17, 2016 and is uptrending. Dimensional Fund Advisors LP holds 240,663 shares or 0.01% of its portfolio. Kestrel Invest Mgmt has invested 3.78% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG). State Board Of Administration Of Florida Retirement Sys invested in 0% or 54,227 shares. Renaissance Technology Ltd Liability has 308,800 shares for 0% of their portfolio. 80,000 shares were sold by Taylor William Charles, worth $1.16M. The firm's quarterly revenue was up 31.4% on a year-over-year basis. research analysts expect that MiMedx Group will post 0.24 earnings per share for the current year. MDXG's profit will be $12.23M for 27.18 P/E if the $0.11 EPS becomes a reality. The value of the investment in Mimedx Group Inc decreased from $23,604,000 to $18,494,000 a change of 7.3% quarter over quarter.

Among 8 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Strs Ohio reported 65,800 shares. (NYSE:WBC) on Thursday, August 24 with "Buy" rating. Bnp Paribas Arbitrage, a New York-based fund reported 3,997 shares.

Since May 18, 2017, it had 0 insider purchases, and 2 selling transactions for $1.24 million activity. We have $11.80 PT which if reached, will make NASDAQ:MDXG worth $38.10 million more.

Investors sentiment decreased to 1.05 in Q2 2017. Its up 0.59, from 1.43 in 2017Q1. It increased, as 68 investors sold SBUX shares while 409 reduced holdings. 104 funds opened positions while 473 raised stakes. Vanguard Gp accumulated 5.66 million shares. Moreover, Lederer And Associates Invest Counsel Ca has 1.97% invested in Starbucks Corporation (NASDAQ:SBUX) for 35,120 shares. Capstone Asset Com holds 0.02% or 47,450 shares in its portfolio. Voya Management Lc has invested 0.01% in WABCO Holdings Inc. Public Employees Retirement Association Of Colorado invested in 0.01% or 10,780 shares. State Of Wisconsin Board has 30,000 shares for 0% of their portfolio. (NYSE:WBC). Asset Management One Ltd holds 85,472 shares.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER